With up to a quarter of nonsmall-cell lung cancer patients treated with pembrolizumab "around 5 years from now, that completely changes our mindset," says David Graham, MD, Levine Cancer Institute.
Medscape Medical News
Original Article: 1-in-4 NSCLC Patients Alive at 5 Years After Pembrolizumab